Journal of hypertension. Supplement : official journal of the International Society of Hypertension最新文献_第5页

Profile of patients with type 2 diabetes in France and Italy. 法国和意大利2型糖尿病患者概况

Journal of hypertension. Supplement : official journal of the International Society of Hypertension Pub Date : 2008-09-01

Faiez Zannad, Enrico Agabiti-Rosei

{"title":"Profile of patients with type 2 diabetes in France and Italy.","authors":"Faiez Zannad, Enrico Agabiti-Rosei","doi":"","DOIUrl":"","url":null,"abstract":"In addition to the prevention and treatment of macro- and microvascular complications, management goals for patients with type 2 diabetes include reducing the risk of cardiovascular events with a view to improving quality of life. A number of epidemiological and observational cohort studies have been published in Italy and France in an effort to determine the patient profile of individuals with type 2 diabetes in these countries and to gather data on current clinical practice and prescribing patterns. The results of the studies confirm that cardiovascular risk factors, such as hypertension and elevated cholesterol, commonly occur in patients with type 2 diabetes and that these co-morbid conditions are not well controlled. As a consequence, both macro- and microvascular complications are prevalent in this patient population. It is clear that the management of type 2 diabetes in France and Italy is suboptimal. In both primary and specialist care, treatment guidelines need to be reinforced and a more aggressive approach needs to be adopted in the treatment of modifiable cardiovascular risk factors and in particular hypertension. Collectively, the available data highlight the importance of managing global cardiovascular risk within the context of diabetes care. Greater adherence to therapeutic targets recommended in guidelines will ensure that greater proportions of patients attain these treatment goals thereby reducing diabetes-related morbidity and mortality.","PeriodicalId":16074,"journal":{"name":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","volume":"26 3","pages":"S3-6"},"PeriodicalIF":0.0,"publicationDate":"2008-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28106865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence. 培哚普利和吲达帕胺固定联合治疗2型糖尿病的疗效和安全性:ADVANCE在现有证据背景下的结果

Journal of hypertension. Supplement : official journal of the International Society of Hypertension Pub Date : 2008-09-01

John Chalmers, Rohina Joshi, Andre Pascal Kengne, Toshiharu Ninomiya, Yufang Bi, Severine Bompoint, Laurent Billot, Anushka Patel

{"title":"Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence.","authors":"John Chalmers, Rohina Joshi, Andre Pascal Kengne, Toshiharu Ninomiya, Yufang Bi, Severine Bompoint, Laurent Billot, Anushka Patel","doi":"","DOIUrl":"","url":null,"abstract":"Objectives: The ADVANCE trial was designed to determine the effects of routine blood pressure lowering using a fixed combination of perindopril-indapamide on major vascular outcomes in patients with type 2 diabetes, regardless of initial blood pressure levels or the use of other blood pressure-lowering drugs, including angiotensin-converting enzyme inhibitors.Methods: After a 6-week run-in period, 11,140 high-risk individuals with type 2 diabetes were randomized to fixed combination perindopril-indapamide or matching placebo, in addition to current therapy. The two primary outcomes were composites of major macrovascular and major microvascular events, analysed jointly and separately by intention to treat.Results: The reduction in blood pressure in participants assigned to active treatment was 5.6/2.2 mmHg greater than that observed in the control group. Active treatment reduced the risk of the combined primary outcome, a major macrovascular or microvascular event by 9% (P = 0.041) and resulted in a 14% (P = 0.025) reduction in all-cause mortality and an 18% (P = 0.027) reduction in cardiovascular mortality. There were reductions of 14% (P = 0.02) in total coronary events and 21% (P < 0.0001) in total renal events. The treatment was well tolerated, with 73% and 74% of patients in the active treatment and placebo groups still adherent to randomized therapy after an average of 4.3 years of follow-up.Conclusions: Routine treatment with the fixed combination of perindopril and indapamide was well tolerated and reduced the risk of death and major vascular events, regardless of the initial blood pressure level or concomitant treatments received. The results suggest that for every 79 patients treated in this manner, one death would be avoided over 5 years.","PeriodicalId":16074,"journal":{"name":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","volume":"26 3","pages":"S21-7"},"PeriodicalIF":0.0,"publicationDate":"2008-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28106786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Blood pressure control, risk factors and cardiovascular prognosis in patients with diabetes: 30 years of progress. 糖尿病患者血压控制、危险因素与心血管预后:30年进展

Journal of hypertension. Supplement : official journal of the International Society of Hypertension Pub Date : 2008-09-01

Jean-Jacques Mourad, Sylvain Le Jeune

{"title":"Blood pressure control, risk factors and cardiovascular prognosis in patients with diabetes: 30 years of progress.","authors":"Jean-Jacques Mourad, Sylvain Le Jeune","doi":"","DOIUrl":"","url":null,"abstract":"Hypertension is a major co-morbidity for type 2 diabetes, and an important modifiable risk factor for vascular events. Therefore, treatment of diabetes and its risk factors is important to minimize complications, and much progress has been made over the past 30 years. The UKPDS trial showed that intensive glycaemic and blood pressure control reduced the risk of vascular events. In the HOT study, the addition of aspirin to patients with diabetes and controlled hypertension decreased the risk of myocardial infarction. Blood pressure control with angiotensin-converting enzyme inhibitors in MICRO-HOPE also showed significant reductions in the risk of vascular complications, and blockers of the renin-angiotensin system produced substantial renal protective effects in patients with hypertension and diabetes. Statin therapy in the HPS and CARDS studies was effective in the primary prevention of cardiovascular disorders. Finally, an intensive multifactorial intervention achieved sustained reduction in the risk of vascular complications and death in patients with type 2 diabetes in the Steno-2 study. Nevertheless, the major coronary event risk remains high in type 2 diabetes patients, and the results of the ADVANCE trial provided a step forward in treatment.","PeriodicalId":16074,"journal":{"name":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","volume":"26 3","pages":"S7-13"},"PeriodicalIF":0.0,"publicationDate":"2008-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28106866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Introduction: advances in the prevention of cardiovascular disease in patients with diabetes. 导言:糖尿病患者心血管疾病预防的研究进展。

Journal of hypertension. Supplement : official journal of the International Society of Hypertension Pub Date : 2008-09-01

John Chalmers, Alberto Zanchetti

引用次数: 0

Introduction: advances in the prevention of cardiovascular disease in patients with diabetes. 导言:糖尿病患者心血管疾病预防的研究进展。

Journal of hypertension. Supplement : official journal of the International Society of Hypertension Pub Date : 2008-09-01 DOI: 10.1097/01.HJH.0000334071.19952.E7

J. Chalmers, A. Zanchetti

{"title":"Introduction: advances in the prevention of cardiovascular disease in patients with diabetes.","authors":"J. Chalmers, A. Zanchetti","doi":"10.1097/01.HJH.0000334071.19952.E7","DOIUrl":"https://doi.org/10.1097/01.HJH.0000334071.19952.E7","url":null,"abstract":"In France and Italy, as in the rest of the world, the epidemic of diabetes is gathering pace [1]. In these pages, Zannad and Agabiti-Rosei [2] document the profile of patients with type 2 diabetes in these two countries and confirm the frequent co-existence of diabetes, raised blood pressure, and elevated cholesterol. They also confirm the wide gap between recommended targets for blood pressure, blood glucose and cholesterol and the levels actually achieved in clinical practice [2]. In turn they describe data from the ‘Forlife’ study in Italy [3] and the ‘Phenomen’ study in France [4], documenting the high levels of both microvascular and macrovascular disease. Between one quarter and one third of patients with type 2 diabetes have well-documented renal disease and similar proportions have experienced a coronary event [2–4]. These findings have recently been confirmed in another Italian survey, the IPERDIA study [5], showing that type 2 diabetes is three times more prevalent among individuals with hypertension than in the general population and is associated with a high prevalence of cardiovascular disorders.","PeriodicalId":16074,"journal":{"name":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","volume":"26 3 1","pages":"S1-2"},"PeriodicalIF":0.0,"publicationDate":"2008-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79909565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Blood pressure control, risk factors and cardiovascular prognosis in patients with diabetes: 30 years of progress. 糖尿病患者血压控制、危险因素与心血管预后:30年进展

Journal of hypertension. Supplement : official journal of the International Society of Hypertension Pub Date : 2008-09-01 DOI: 10.1097/01.HJH.0000334072.97080.33

J. Mourad, S. Le Jeune

{"title":"Blood pressure control, risk factors and cardiovascular prognosis in patients with diabetes: 30 years of progress.","authors":"J. Mourad, S. Le Jeune","doi":"10.1097/01.HJH.0000334072.97080.33","DOIUrl":"https://doi.org/10.1097/01.HJH.0000334072.97080.33","url":null,"abstract":"Hypertension is a major co-morbidity for type 2 diabetes, and an important modifiable risk factor for vascular events. Therefore, treatment of diabetes and its risk factors is important to minimize complications, and much progress has been made over the past 30 years. The UKPDS trial showed that intensive glycaemic and blood pressure control reduced the risk of vascular events. In the HOT study, the addition of aspirin to patients with diabetes and controlled hypertension decreased the risk of myocardial infarction. Blood pressure control with angiotensin-converting enzyme inhibitors in MICRO-HOPE also showed significant reductions in the risk of vascular complications, and blockers of the renin-angiotensin system produced substantial renal protective effects in patients with hypertension and diabetes. Statin therapy in the HPS and CARDS studies was effective in the primary prevention of cardiovascular disorders. Finally, an intensive multifactorial intervention achieved sustained reduction in the risk of vascular complications and death in patients with type 2 diabetes in the Steno-2 study. Nevertheless, the major coronary event risk remains high in type 2 diabetes patients, and the results of the ADVANCE trial provided a step forward in treatment.","PeriodicalId":16074,"journal":{"name":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","volume":"17 1","pages":"S7-13"},"PeriodicalIF":0.0,"publicationDate":"2008-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79431754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 51

From macro- to microcirculation: benefits in hypertension and diabetes. 从宏观到微循环:对高血压和糖尿病有益。

Journal of hypertension. Supplement : official journal of the International Society of Hypertension Pub Date : 2008-09-01

Enrico Agabiti-Rosei

引用次数: 0

Implications of the ADVANCE study for clinical practice. ADVANCE研究对临床实践的意义。

Journal of hypertension. Supplement : official journal of the International Society of Hypertension Pub Date : 2008-09-01

Faiez Zannad

{"title":"Implications of the ADVANCE study for clinical practice.","authors":"Faiez Zannad","doi":"","DOIUrl":"","url":null,"abstract":"Blood pressure is an important determinant of the risk of macro- and microvascular vascular complications in patients with type 2 diabetes. Current European guidelines for the management of hypertension recommend lowering blood pressure in patients with type 2 diabetes to reduce the risk of cardiovascular events. The Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial (n = 11,140), is the first trial designed to address the issue of whether routine blood pressure lowering with the fixed combination of perindopril/indapamide is beneficial in patients with diabetes with a broad range of baseline blood pressure values. In addition, it aimed to determine if clinical benefit is achieved over and above that observed with background angiotension-converting enzyme inhibitor therapy. In the perindopril/indapamide arm, the reduction in blood pressure led to significant clinical benefits in patients with type 2 diabetes, irrespective of baseline blood pressure values, and subsequently improved mortality rates, and macro- and microvascular outcomes, beyond the improvements associated with patients' existing antihypertensive therapies. ADVANCE is a robust well-designed trial, the results of which are directly applicable to current clinical practice. The ADVANCE study defines the relevant blood pressure goals for patients with type 2 diabetes who are at high risk of cardiovascular events and underscores the benefits of aggressive blood pressure reduction even in normotensive patients with diabetes. It is likely that these findings will have a significant impact on the management of patients with type 2 diabetes. In view of the evidence indicating that clinical benefits obtained with the perindopril/indapamide combination can be expected even in patients who are normotensive, vascular risk rather than initial blood pressure should be employed to determine appropriate treatment protocols in patients with type 2 diabetes.","PeriodicalId":16074,"journal":{"name":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","volume":"26 3","pages":"S29-32"},"PeriodicalIF":0.0,"publicationDate":"2008-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28106787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Profile of patients with type 2 diabetes in France and Italy. 法国和意大利2型糖尿病患者概况

Journal of hypertension. Supplement : official journal of the International Society of Hypertension Pub Date : 2008-09-01 DOI: 10.1097/01.HJH.0000334076.50446.E5

F. Zannad, E. Agabiti-Rosei

{"title":"Profile of patients with type 2 diabetes in France and Italy.","authors":"F. Zannad, E. Agabiti-Rosei","doi":"10.1097/01.HJH.0000334076.50446.E5","DOIUrl":"https://doi.org/10.1097/01.HJH.0000334076.50446.E5","url":null,"abstract":"In addition to the prevention and treatment of macro- and microvascular complications, management goals for patients with type 2 diabetes include reducing the risk of cardiovascular events with a view to improving quality of life. A number of epidemiological and observational cohort studies have been published in Italy and France in an effort to determine the patient profile of individuals with type 2 diabetes in these countries and to gather data on current clinical practice and prescribing patterns. The results of the studies confirm that cardiovascular risk factors, such as hypertension and elevated cholesterol, commonly occur in patients with type 2 diabetes and that these co-morbid conditions are not well controlled. As a consequence, both macro- and microvascular complications are prevalent in this patient population. It is clear that the management of type 2 diabetes in France and Italy is suboptimal. In both primary and specialist care, treatment guidelines need to be reinforced and a more aggressive approach needs to be adopted in the treatment of modifiable cardiovascular risk factors and in particular hypertension. Collectively, the available data highlight the importance of managing global cardiovascular risk within the context of diabetes care. Greater adherence to therapeutic targets recommended in guidelines will ensure that greater proportions of patients attain these treatment goals thereby reducing diabetes-related morbidity and mortality.","PeriodicalId":16074,"journal":{"name":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","volume":"22 1","pages":"S3-6"},"PeriodicalIF":0.0,"publicationDate":"2008-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81015547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

From microcirculation to cardiac event: protection with Preterax. 从微循环到心脏事件:Preterax的保护作用。

Journal of hypertension. Supplement : official journal of the International Society of Hypertension Pub Date : 2008-06-01 DOI: 10.1097/01.HJH.0000320753.31109.BC

P. Camici

引用次数: 8